Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

Theranexus announces a successful clinical pharmacokinetic study as part of the development of its drug candidates THN201 and THN101
21/03/2018
Download PDF File (309 Ko)

Theranexus and the Collège de France sign a research agreement on Astrocyte-Neuron interactions
15/03/2018
Download PDF File (187 Ko)

Theranexus announces issuance of European patent covering its drug candidate thn102 for treatment of narcolepsy and Parkinson's disease>
11/01/2018
Télécharger le PDF (801 Ko)

Information on the total number of voting rights and shares (french only)
05/01/2018
Download PDF File (656 Ko)

End of stabilization period and implementation of a liquidity contract (french only)
18/12/2017
Download PDF File (917 Ko)

Information on the total number of voting rights and shares (french only)
18/12/2017
Download PDF File (650 Ko)

Success of Theranexus' IPO on Euronext Growth in Paris
25/10/2017
Download PDF File (917 Ko)

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris
28/09/2017
Download PDF File (637 Ko)

Theranexus announces issuance of US patent covering its drug candidate THN102 for treatment of narcolepsy and Parkinson's disease
22/09/2017
Download PDF File (222 Ko)

Theranexus renforce son équipe de management avec l'arrivée de Thierry Lambert en tant que directeur financier
14/09/2017
Download PDF File (210 Ko)